A blood purification apparatus that includes a blood purifier, a vascular access flow path, a cleaning solution flow path, and a drainage flow path. The blood purifier has an inner portion divided by a semi-permeable membrane into a first portion and a second portion. The vascular access flow path is connected to the blood purifier and is in communication with the first portion. The cleaning solution flow path is connected to the blood purifier and is in communication with the first portion. The drainage flow path is connected to the blood purifier and is in communication with the second portion. The cleaning solution flow path is provided with a blood pump capable of bidirectionally feeding a fluid. An open-close valve is provided in each of the vascular access flow path and the drainage flow path.

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma.

The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SA RS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL-6, Troponin T, and D-dimer.

A dialysis fluid system includes a dialysis fluid inlet; a dialysis fluid outlet; a pump positioned and arranged to pump dialysis fluid through the dialysis fluid inlet and the dialysis fluid outlet; and an inductive heater located between the dialysis fluid inlet and the dialysis fluid outlet, the inductive heater including a fluid flowpath positioned and arranged to receive non-heated dialysis fluid from the dialysis fluid inlet and to output heated dialysis fluid to the a dialysis fluid outlet, a conductive heater element located within the fluid flowpath so as to be or act as a secondary coil of a transformer, and a primary coil of the transformer located outside of the fluid flowpath and positioned so as to magnetically induce a current into the conductive heater element, causing the conductive heater element and surrounding fluid to heat.

A hemodiafiltration system with a disposable pumping unit is disclosed. An example system includes a medical fluid pump actuator, a medical fluid heater, a blood filter and a disposable unit. The example disposable unit includes a medical fluid cassette portion including a medical fluid cassette housing configured to be operatively connected to the medical fluid pump actuator to pump medical fluid through the medical fluid cassette portion when the medical fluid cassette portion is in fluid communication with a medical fluid source. The example medical fluid cassette portion is also configured to be placed in fluid communication with the blood filter and with an extracorporeal circuit communicating with the blood filter, the fluid communication enabling hemodiafiltration to be performed. The example disposable unit also includes a heater bag configured to be placed in operable communication with the medical fluid heater and in fluid communication with the medical fluid cassette portion.

A hemodiafiltration system with a disposable pumping unit is disclosed. An example system includes a medical fluid pump actuator, a medical fluid heater, a blood filter and a disposable unit. The example disposable unit includes a medical fluid cassette portion including a medical fluid cassette housing configured to be operatively connected to the medical fluid pump actuator to pump medical fluid through the medical fluid cassette portion when the medical fluid cassette portion is in fluid communication with a medical fluid source. The example medical fluid cassette portion is also configured to be placed in fluid communication with the blood filter and with an extracorporeal circuit communicating with the blood filter, the fluid communication enabling hemodiafiltration to be performed. The example disposable unit also includes a heater bag configured to be placed in operable communication with the medical fluid heater and in fluid communication with the medical fluid cassette portion.

The embodiments provide a bioengineered artificial functional liver which is connected to a patient suffering from acute liver failure and would functional like an ectopic liver. The device uses the cells derived from the patient's own body thereby nullifying the chances of self/non-self-recognition and related immune activation and rejection. The extracted liver cells are grown on a customized 3D matrix called as 3D cell cartridge and these cell cartridges individually function as miniature liver assemblies. Multiple such assemblies when working in parallel would rescue the condition of liver failure. A microfluidic chamber is built with the similar network as found in the liver and the chamber has flow circuits for plasma/de-cellularised blood and the flow circuits are lined by a coculture of hepatocytes, endothelial cells and fibroblasts. The array of cells in the chamber serve as a miniature liver and multiple such arrays will be stacked to achieve a significant hepatic function.

A peritoneal dialysis system includes a control unit is programmed to cause (i) a pressure sensor to take a first pressure reading of a reference chamber with a pneumatic valve closed, (ii) a pump actuator to pump fresh dialysis fluid through a fresh dialysis fluid pathway into a patient line expandable chamber, expanding the expandable chamber into a dome, (iii) the pneumatic valve to open, allowing the reference chamber to communicate pneumatically with any air in the dome, (iv) the pressure sensor to take a second pressure reading with the pneumatic valve open, (v) the first and second pressure readings to be used with the ideal gas law to determine an amount of air in the dome, and (vi) the amount of air in the dome and a known volume of the dome to be used to determine an amount of fresh dialysis fluid delivered into the expandable chamber.

Process and system for acellular therapy in a human subject are provided. The process and system relate to an acellular therapy using therapeutic extracellular vehicles fused to biological material obtained from the subject, via transfusion by extracorporeal systems. The process for acellular therapy is in a subject in need of such therapy.

Techniques and apparatus for de-priming processes are described. For example, in one embodiment, an apparatus may include at least one processor and a memory coupled to the at least one processor, the memory may include instructions that, when executed by the processor, may cause the at least one processor to determine a priming volume of a primer fluid infused into a priming system associated with the patient during a priming phase of the dialysis treatment, cause an ultrafiltration rate of an ultrafiltration pump of the dialysis machine in fluid communication with the patient to be changed from a treatment ultrafiltration rate to a de-priming ultrafiltration rate to remove the priming volume over a de-priming time period, and cause, after the de-priming time period, the ultrafiltration rate of the ultrafiltration pump to be changed back the treatment ultrafiltration rate. Other embodiments are described.